Sanofi-aventis

Editas Medicine is a pioneering biotechnology company based in Cambridge, MA, dedicated to harnessing the power of CRISPR gene editing to develop transformative medicines for individuals worldwide living with serious diseases. With a robust pipeline of experimental medicines, Editas Medicine aims to discover, manufacture, and commercialize durable genomic therapies that have the potential to revolutionize the treatment of various conditions. Driven by a commitment to delivering transformative medicines to a wide range of patients, Editas Medicine utilizes the innovative CRISPR technology to revise, remove, and replace DNA in a highly targeted manner. With a focus on developing transformative and durable treatments, the company's mission is to improve the lives of individuals affected by serious diseases through cutting-edge gene editing techniques.Generated from the website

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.